Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 142Endometrial Neoplasms 85Uterine Cervical Neoplasms 71Breast Neoplasms 42Fallopian Tube Neoplasms 38Colorectal Neoplasms 34Carcinoma, Non-Small-Cell Lung 32Pancreatic Neoplasms 24Neoplasms 23Prostatic Neoplasms 22Neoplasm Metastasis 21Stomach Neoplasms 19Triple Negative Breast Neoplasms 18Urinary Bladder Neoplasms 17Esophageal Neoplasms 17Melanoma 16Squamous Cell Carcinoma of Head and Neck 15Lung Neoplasms 15Carcinoma, Renal Cell 15Carcinoma, Ovarian Epithelial 15Head and Neck Neoplasms 14Sarcoma 13Carcinoma, Hepatocellular 13Uterine Neoplasms 11Colonic Neoplasms 11Cholangiocarcinoma 11Carcinoma, Transitional Cell 11Rectal Neoplasms 10Vulvar Neoplasms 9Small Cell Lung Carcinoma 9

Interventions

trifluridine tipiracil drug combination 1Oxaliplatin 1Nivolumab 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenomatous Polyposis Coli × Gynecologic × 30 days × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡